Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[100] RCT	5165 people followed up Further report of reference [102]	Proportion of people reporting an adverse effect 40 months 76% with enalapril given for 3 to 4 years 72% with placebo Absolute numbers not reported	Significance not assessed
[100] RCT	5165 people followed up Further report of reference [102]	Proportion of people with dizziness or fainting 40 months 46% with enalapril given for 3 to 4 years 33% with placebo Absolute numbers not reported	Significance not assessed
[100] RCT	5165 people followed up Further report of reference [102]	Proportion of people with cough 40 months 34% with enalapril given for 3 to 4 years 27% with placebo Absolute numbers not reported	Significance not assessed
[100] RCT	5165 people followed up Further report of reference [102]	Proportion of people with angio-oedema 40 months 1% with enalapril given for 3 to 4 years 1% with placebo Absolute numbers not reported	Significance not assessed
[98] Systematic review	10,235 people with vascular disease 3 RCTs in this analysis	Proportion of people who withdrew because of adverse effects 732/5139 (14%) with ACE inhibitor 343/5096 (7%) with placebo	RR 2.30 95% CI 1.34 to 3.95	Small effect size	placebo
[98] Systematic review	10,974 people with vascular disease 3 RCTs in this analysis	Proportion of people with hypotension 38/5490 (0.7%) with ACE inhibitors 26/5484 (0.5%) with placebo	RR 1.79 95% CI 0.68 to 4.71		Not significant
[98] Systematic review	17,587 people with vascular disease 2 RCTs in this analysis	Proportion of people with syncope 203/8803 (2.3%) with ACE inhibitors 162/8784 (1.8%) with placebo	RR 1.24 95% CI 1.02 to 1.52	Small effect size	placebo
[98] Systematic review	18,915 people with vascular disease 3 RCTs in this analysis	Proportion of people with cough 1726/9476 (18%) with ACE inhibitors 1183/9439 (12%) with placebo	RR 1.67 95% CI 1.22 to 2.29	Small effect size	placebo
Discontinuation of treatment
[100] RCT	5165 people followed up Further report of reference [102]	Proportion of people permanently discontinuing treatment 40 months 8% with enalapril given for 3 to 4 years 5% with placebo Absolute numbers not reported	Significance not assessed